Side-by-side · Research reference

AdipotidevsCardiogen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BAnimal-MechanisticHUMAN-REVIEWED5/46 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

01Mechanism of Action

Parameter

Adipotide

Cardiogen

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Cardiovascular cell gene expressionKhavinson 2022

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

Cardiogen

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

Subcutaneous injection

Frequency

Not specified in available data

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

Evidence basis

Preclinical animal models only

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Human data

None — no clinical trials reported

—

Standard dose

—

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

Duration

—

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

Cardiogen

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

Cardiogen

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

Unknown — no antibody development studies published

Injection site reactions

—

Mild erythema, induration (presumed)

Systemic adverse events

—

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

Long-term safety

—

Unknown — no extended human trials indexed in PubMed

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

05Administration Protocol

Parameter

Adipotide

Cardiogen

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Variable — often evening injection. No established circadian preference.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

5. Needle

—

27–30G insulin syringe, 45° angle for subcutaneous administration.

06Stack Synergy

Adipotide

— no documented stacks

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis